May 31, 2019
Ono Pharmaceutical said on May 30 that it has submitted an application in Japan for its anti-PD-1 antibody Opdivo (nivolumab) for an additional indication of unresectable advanced/relapsed esophageal cancer. The application is based on the results of a global PIII...read more